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Prevalence and correlates of central venous
catheter use among haemodialysis patients
in the Irish health system - a national study
Wael F. Hussein1,2*, Husham Mohammed1,2, Leonard Browne2, Liam Plant3,4 and Austin G. Stack1,2,5
Abstract
Background: Central venous catheters (CVC) are associated with substantial morbidity and mortality among
patients undergoing haemodialysis (HD), yet they are frequently used as the primary vascular access for many
patients on HD. The goal of this study was to determine the prevalence and variation in CVC use across centres
in the Irish health system.
Methods: Data from the National Kidney Disease Clinical Patient Management System (KDCPMS) was used to determine
CVC use and patterns across centres. Data on demographic characteristics, primary cause of end-stage kidney
disease (ESKD), comorbid conditions, laboratory values and centre affiliation were extracted for adult HD patients (n = 1,
196) who were on dialysis for at least three months up to end of December 2016. Correlates of CVC use were explored
using multivariable logistic regression.
Results: Overall prevalence of CVC use was 54% and varied significantly across clinical sites from 43% to 73%, P < 0.001.
In multivariate analysis, the likelihood of CVC use was lower with increasing dialysis vintage, OR 0.40 (0.26–0.60) for
4 years vs 1 year vintage, rising serum albumin, OR 0.73 (0.59–0.90) per 5 g/L), and with cystic disease as a cause of
ESKD, OR 0.38 (95% CI 0.21–0.6). In contrast, catheter use was greater for women than men, OR 1.77 (1.34–2.34)
and for 2 out of 10 regional dialysis centres, OR 1.98 (1.02–3.84) and OR 2.86 (1.67–4.90) respectively compared to
referent group).
Conclusions: Catheters are the predominant type of vascular access in patients undergoing HD in the Irish
health system. Substantial centre variation exists which is not explained by patient-level characteristics.
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Background
Patients who develop kidney failure and require haemodi-
alysis (HD) experience substantial morbidity and mortality
[1, 2]. It is well established that the type of permanent vas-
cular access, central venous catheter (CVC), arteriovenous
fistula (AVF) or graft (AVG), is a major determinant of
subsequent morbidity and overall patient survival. For
patients who are treated with HD, the risks of major
cardiovascular events, fatal and non-fatal infections and
overall mortality are far greater with catheters than with
AV fistula [3–6]. Although the AV fistula is cited as the
preferred access for most patients, a majority of patients
are treated with tunnelled dialysis catheters [7–9]. In
response, recommendations from professional societies
and governmental organisations, along with clinical guide-
lines from expert groups, have advocated strongly for
changes in clinical practice that would favour greater
utilization of the AV fistula over catheter use in order to
improve patient outcomes [10–12].
Observational studies, both national and international,
have demonstrated substantial variation in vascular
access utilisation among HD patients [9, 13–16]. Evi-
dence suggests that both patient-level characteristics and
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facility-related factors contribute to the observed vari-
ation in vascular access provision [14–19]. The extent to
which each set of factors contribute to the overall extent
of variation in utilisation is unclear. On one hand, there
is good evidence to invoke patient-level characteristics
such as age, sex, race, presence of medical conditions,
and patient preference as important determinants of
access type [9]. On the other hand, emerging evidence
suggests that variation in the rates of vascular access
across HD centres persist even after correction of
patient-related factors and implicate factors external to
the patients such as process of care and lack of compre-
hensive multidisciplinary team programs [16]. A detailed
understanding of the utilisation of vascular access within
health systems in fundamental to strategic planning and
organisation of access services in order to improve
patients outcomes.
National data on the epidemiology of vascular access
(VA) is lacking within the Irish health system, which
may hamper strategic decision-making on the organisa-
tion and delivery of optimal vascular access care. A
recent cross-sectional study by McCann et al. found that
the prevalence of tunnelled dialysis catheters across Irish
dialysis centres was 52%, ranging from 35 to 80% across
participating centres [20]. The survey identified deficien-
cies in the organisation and delivery of vascular access
provision including lack of dedicated theatre time for
vascular surgery as contributing factors. Recently, Ireland,
as part of its national renal strategy, has implemented a
national patient electronic system, the “Kidney Disease
Clinical Patient Management System (KDCPMS)”, in order
to track the care and outcomes of patients with moderate
to advanced CKD within the health system. This system
has provided a unique opportunity to gain greater insight
into the provision of HD access care in the Irish health
system and facilitate studies to explore variation across
centres and to support quality improvement initiatives.
The goal of this study was to describe the prevalence
of vascular access among prevalent HD patients in the
Irish health system and examine for variation in access
use across clinical sites. Moreover, we sought to deter-
mine whether any observed variation could be explained
by differences in measureable demographic, clinical and
dialysis-related factors.
Methods
Clinical setting
Renal replacement therapies in the Republic of Ireland are
provided through 11 primary kidney centres, organised
into six hospital groups. Under supervision of these
primary centres, haemodialysis (HD) for adult patients is
organised and supervised across 20 dialysis units. Every
patient on HD has a “centre of primary medical supervi-
sion” at which their care is managed, including arrange-
ments for provision of vascular access placement.
KDCPMS is a kidney-specific national information sys-
tem that tracks patients from late-stage CKD across the
transition to end-stage kidney disease (ESKD) across all
dialysis centres in Ireland. The system interfaces directly
with local hospital information systems to capture real-
time data on demographics and laboratory results for
individual patients. Data such as primary cause of ESKD,
comorbid conditions, medications, and ancillary notes
on clinical care delivery are manually entered by users at
site of care. Each renal centre has a local KDCPMS
supervisor, whose responsibilities include user manage-
ment, data reporting and quality control.
Over the last several years, renal centres in Ireland were
incrementally added on KDCPMS. In 2017, all units in the
Republic of Ireland were included in the system. At the
end of December 2016, the observation time-point for this
paper, 17 HD facilities from 10 centres of primary medical
supervision, had fully enrolled in KDCPMS.
Fig. 1 Flow chart of study cohort. KDCPMS: Kidney Disease Clinical Patient Management System
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Study design and data sources
We conducted a national cross-sectional study of vascu-
lar access among adult prevalent HD patients who were
alive and active on HD on 31/12/2016 at KDCPMS-
participating centres for at least 3 months - Fig. 1. We
included patients who received a minimum of 6 dialysis
treatment sessions per month from October to December
2016. Patients who had their primary medical supervision
at a site that was not active on KDCPMS were excluded.
Patients with no recorded access type at any session in
November and December 2016 were also excluded.
Data were captured from KDCPMS on demographic
characteristics, comorbid conditions, primary cause of
ESKD, vascular access type, location of medical supervi-
sion, and monthly laboratory values for all HD patients
during the study period. The type of vascular access
recorded for each patient between November 1st and
December 31st 2016 was retrieved, and vascular access
assignment was based on the last recorded access used
for HD in this period. Primary cause of kidney disease
and comorbid diagnoses were collapsed into categories
and classified as per the US Renal Data System. A
patient was considered to have hypertension or diabetes
if these conditions were listed among the comorbid con-
ditions or if diabetes or hypertension was among the
causes of kidney disease. Laboratory variables measured
between 1/9/2016 and 31/12/2016 were retrieved and
the time-weighted median value for each test type was
determined and included in the final dataset. Ten clin-
ical sites that were active on KDCPMS in 2016 were
included in this study. For the purposes of this study,
patients who were treated with an AVG (n = 14) were
grouped with those using an AVF. Patient assignment to
a specific dialysis centre was based on last “location of
primary medical supervision” during 2016. Ethical ap-
proval was not sought as this study was part of a quality
improvement initiative and satisfied the ethical and
information governance for analysis of secondary health
data for improvement in population health [21].
Statistical methods
Baseline characteristics were described for the whole
population, by type of access, and by HD centre, as
counts and proportion for categorical variables, and as
means and standard deviations for continuous variables.
The number of patients in each centre was suppressed
to maintain centre anonymity. The Chi-square and
ANOVA tests were used to test for differences between
groups as appropriate. Missing data were imputed using
predictive mean matching with 50 iterations, generating
5 complete datasets. Multivariable logistic regression
was used to explore factors associated with CVC use
versus AVF. The explanatory variables were classified as
demographic, primary cause of ESKD, comorbid medical
conditions, laboratory indicators of health, and dialysis
centre. Model building progressed in a manual fashion
based on univariate associations, clinical reasoning and
previous published literature. A final model was con-
structed to explore the relative contribution of all ex-
planatory factors with the presence of catheters. The
associations of explanatory factors with catheter pres-
ence were represented by adjusted odds-ratios (AOR)
and 95% CI. For each model, the C-statistic was calcu-
lated to assess the model performance. Several sensitiv-
ity analyses were performed to assess the robustness of
our results. First, we repeated the analysis using the
first recorded result for each laboratory value (within
the period from 1st of November to 31st of December
2016) instead of the weighted medians described
above. Second, we re-analysed the data using only
patients with complete data on all measured variables
(complete case analysis). The final analytic dataset was
constructed and analysed using R version 3.4.
Results
From a total of 1234 patients satisfying the inclusion
criteria, 38 patients were excluded, and the remaining
1196 patients were included in the analysis (Fig. 1).
Descriptive statistics
The baseline characteristics of the study population by
type of vascular access are shown in Table 1. Overall,
54% of the patients received dialysis through CVC. The
mean age was 65 years, 31% of the patients were 75 years
of age or older, and 37% of patients were female. The
prevalence of diabetes and hypertension were 31% and
56% respectively. Patients with CVC had a higher pro-
portion of older patients and females. Moreover, a higher
proportion of patients were dialysing with a CVC rather
than AVF in the first year of dialysis compared to later
vintage periods.
The median number of patients per centre was 103
(IQR: 91–147). The distribution of baseline characteris-
tics across dialysis centres is shown in Additional file 1:
Table S1. CVC use varied significantly across participating
dialysis centres, ranging from 43% to 73%, P < 0.0001.
Significant variation also existed across clinical sites in re-
lation to age, recorded comorbid medical conditions, pri-
mary kidney disease, laboratory values and vintage groups.
Association of Patient-level Characteristics with CVC use
The relationship between demographic and lifestyle fac-
tors, and comorbid conditions with CVC use was explored
in a series of univariable and multivariable models of
increasing complexity. In the unadjusted models, increas-
ing age and female sex were significantly associated with
CVC use (Table 2). Patients with cystic kidney disease as
primary cause of ESKD (compared to glomerulonephritis,
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Table 1 Patient characteristics by type of vascular access
Variable
Mean (SD) or Frequency %
Overall Arteriovenous Fistula Central Venous Catheter p-value
(n = 1196)
Vascular Access Type 45.7% 54.3%
Demographic Characteristic (%)
Age (year) 64.8 (15.1) 63.2 (15.2) 66.1 (14.9) 0.0009
Age Group 0.0138
< 65 42.7 47.0 39.1
65–74 26.5 25.8 27.1
75+ 30.8 27.2 33.7
Female 36.9 30.0 42.7 < 0.0001
Lifestyle Factor (%)
Body mass index (kg/m2) 27.3 (6.5) 27.6 (6.1) 27.1 (6.8) 0.1960
BMI Group 0.0315
< 20 4.8 3.2 6.2
20–25 34.8 33.0 36.5
26–30 33.4 36.6 30.6
> 30 26.9 27.2 26.7
Comorbid conditions (%)
Hypertension 56.4 58.9 54.2 0.1212
Diabetes mellitus 31.4 29.1 33.4 0.1191
Atherosclerotic heart disease 18.6 18.1 19.1 0.7105
Congestive heart disease 15.7 15.4 16 0.8130
Other cardiac disease 15.7 15.4 16 0.8130
Cerebrovascular disease 7.3 5.9 8.5 0.1033
Peripheral vascular disease 5.7 5.9 5.5 0.9202
Primary Kidney Disease (%) < 0.0001
Glomerulonephritis 19.2 20.3 18.3
Diabetes 18.6 18.5 18.8
Hypertension 8.6 10.2 7.2
Cystic kidney disease 6.4 9.5 3.7
Other urologic 9.4 9.5 9.4
Other cause 9.5 9.5 9.6
Unknown/missing 28.2 22.5 33.0
Laboratory values (mean (SD))
Albumin (g/L) 36.8 (4.4) 37.5 (3.9) 36.3 (4.7) < 0.0001
Calcium (mmol/L) 2.3 (0.2) 2.3 (0.2) 2.2 (0.2) 0.0025
Phosphorous (mmol/L) 1.6 (0.4) 1.6 (0.4) 1.5 (0.4) 0.3880
Pre-dialysis creatinine (μmol/L) 731.1 (243.7) 776.8 (236.2) 692.8 (243.5) < 0.0001
Dialysis Vintage (%) < 0.0001
< 1 year 15.6 9.7 20.7
1–4 years 42.6 43.5 41.9
> 4 years 41.7 46.8 37.4
Percentage of missing data: Body mass index (and BMI group): 11.2%, Albumin 21.7%, Calcium 21.6%, Phosphorous 21.6%, Pre-dialysis creatinine 7.5%, Dialysis
Vintage: 0.6%
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referent) experienced significantly lower odds of CVC use
while patients with unknown or missing case of ESKD
had significantly higher odds ratio. Serum albumin and
pre-dialysis creatinine concentrations, both nutritional in-
dicators of health, were associated with significantly lower
odds of CVC. The findings from the univariate analysis
were confirmed in the multivariable analysis. Women
were significantly more likely to have a CVC as their prin-
cipal access than men (OR 1.77, 95% CI 1.34–2.34), and
this association persisted following adjustment for age,
comorbid indicators, and lifestyle factors. Similarly, pa-
tients with ESKD from cystic diseases of the kidney expe-
rienced lower odds of CVC compared to those with a
primary glomerulonephritis (OR 0.38, 95% CI 0.21–0.68).
There was a strong inverse association of dialysis vintage
with CVC use such that patients on HD for 4 years or
more had a 60% lower odds of having a CVC (OR 0.40,
9R% CI 0.26–0.60).
Association of Dialysis Centre with CVC use
The univariable models identified a strong association of
dialysis centre (centre 2 and 4) with CVC use as shown in
Table 3. With sequential adjustment for patient-level char-
acteristics including dialysis vintage, Centres 2 and 4 expe-
rienced higher odds ratios of CVC use (OR 2.01, 95% CI:
1.08–3.75, and 2.56, 95% CI: 1.55–4.25 respectively) com-
pared to the referent Centre 1. Surprisingly, the magni-
tude of the association was virtually unchanged following
adjustment. Our analysis demonstrated that the dialysis
centre had a significant contribution to the performance
of all models, with a Wald test p value of < 0.001. How-
ever, our final model yielded a C-statistic of 0.69-moderate
performance, suggesting that the final set of variables did
not adequately explain variation in use. The association of
dialysis centres with CVC use in the univariable model
and the fully adjusted model is demonstrated in Fig. 2.
Discussion
In this nationally representative study, we describe for
the first time the prevalence and correlates of CVC use
in a contemporary cohort of HD patients in the Irish
health system. Central venous catheters were the pre-
dominant type of vascular access, with a prevalence of
54%. We found that women were significantly more
likely than men to have a CVC in-situ adjusting for
case-mix, and that CVC use became less frequent with
increasing dialysis vintage. Within the health system, we
observed substantial variation in CVC use across dialysis
centres that ranged from 43 to 73%. Quite strikingly
these differences across centres did not diminish when
adjustment was made for baseline differences in demo-
graphic characteristics and comorbid indicators of illness
such that in the final model, 2 out of 10 dialysis centres
continued to experience a 2–3 fold higher use of CVC
than AVF compared to the reference centre. These find-
ings would suggest that additional factors, such as pa-
tient preference, and the structure and organisation of
care delivery prior to and after dialysis initiation, con-
tribute to differences in vascular access provision and
utilisation within the Irish health system.
Despite introduction of evidence-based guidelines and
strategic initiatives by many countries to improve the
provision of AVF and reduce dependency on CVC, this
study in the Irish health system highlights substantial
Table 2 Factors associated with Central Venous Catheter Use
(vs Fistula) in the Irish Health System (Odds Ratios and 95%
Confidence Intervals) – Univariate Analysis
Variable OR (95% Confidence
Intervals)
Demographic factors
Female (vs male) 1.74 (1.37–2.21)****
Age group (years)
< 65 (Referent) 1.00
65–74 1.26 (0.95–1.67)
75 + 1.49 (1.13–1.95)**
Lifestyle Factor
Body mass index (BMI) group (kg/m2)
< 20 1.65 (0.88–3.12)
20–25 (Referent) 1.00
25–30 0.78 (0.58–1.04)
> 30 0.83 (0.61–1.12)
Comorbid conditions
Atherosclerotic heart disease (yes vs no) 1.07 (0.8–1.43)
Diabetes (yes vs no) 1.23 (0.96–1.57)
Hypertension (yes vs no) 0.83 (0.66–1.04)
Primary cause of kidney disease
Glomerulonephritis (Referent) 1.00
Cystic kidney disease 0.43 (0.25–0.75) **
Diabetes 1.13 (0.78–1.63)
Hypertension 0.78 (0.49–1.25)
Other cause of ESKD 1.11 (0.71–1.75)
Other urologic disease 1.09 (0.7–1.72)
Unknown/missing 1.62 (1.15–2.28) **
Laboratory values
Albumin (per 5 g/L) 0.71 (0.61–0.83)****
Pre-dialysis Creatinine (per 50 μmol/L) 0.93 (0.91–0.95)****
Vintage (years)
< 1 (Referent) 1.00
1–4 0.45 (0.31–0.65)****
4+ 0.37 (0.26–0.53)****
Asterisks denote significant p values: * < 0.05, ** < 0.01, *** < 0.001,
**** < 0.0001
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Table 3 Unadjusted and multivariable adjusted Odd Ratios and 95% confidence intervals for Central Venous Catheter use (vs Fistula)
Variable Model 1 Model 2 Model 3 Model 4 Model 5
Dialysis Centre
Centre 1 (Referent) 1.00 1.00 1.00 1.00 1.00
Centre 2 2.01 (1.08–3.75) * 1.86 (0.99–3.50) 1.91 (1.00–3.65)* 1.98 (1.02–3.81)* 1.98 (1.02–3.84)*
Centre 3 0.88 (0.59–1.30) 0.85 (0.57–1.26) 0.77 (0.51–1.16) 0.83 (0.54–1.26) 0.79 (0.51–1.24)
Centre 4 2.56 (1.55–4.25) *** 2.59 (1.55–4.33)*** 2.59 (1.53–4.37)*** 2.61 (1.54–4.43)*** 2.86 (1.67–4.90)***
Centre 5 0.73 (0.45–1.18) 0.69 (0.42–1.14) 0.71 (0.43–1.18) 0.72 (0.43–1.20) 0.79 (0.47–1.33)
Centre 6 0.95 (0.57–1.60) 0.96 (0.57–1.63) 0.87 (0.51–1.50) 0.91 (0.52–1.58) 0.60 (0.32–1.11)
Centre 7 1.51 (0.94–2.43) 1.41 (0.87–2.29) 1.36 (0.83–2.24) 1.47 (0.88–2.45) 1.18 (0.69–2.01)
Centre 8 1.32 (0.87–2.00) 1.36 (0.89–2.07) 1.23 (0.79–1.91) 1.18 (0.75–1.85) 1.31 (0.83–2.06)
Centre 9 0.88 (0.54–1.42) 0.83 (0.51–1.36) 0.74 (0.45–1.23) 0.81 (0.48–1.35) 0.86 (0.51–1.45)
Centre 10 1.02 (0.62–1.68) 0.98 (0.59–1.62) 0.87 (0.52–1.47) 0.90 (0.53–1.52) 0.97 (0.57–1.66)
Demographic Factor
Female (vs male) 1.68 (1.31–2.15)**** 1.79 (1.39–2.31)**** 1.87 (1.44–2.43)**** 1.77 (1.34–2.34)****
Age group (years)
< 65 (Ref) 1.00 1.00 1.00 1.00
65–74 1.30 (0.97–1.74) 1.20 (0.89–1.62) 1.19 (0.87–1.61) 1.05 0.76–1.45)
≥ 75 1.46 (1.10–1.94)** 1.41 (1.05–1.89)* 1.35 (1.00–1.83) 1.15 (0.83–1.60)
Lifestyle factor
Body mass index (BMI) group (kg/m2)
< 20 1.74 (0.91–3.36) 1.81 (0.93–3.53) 1.86 (0.95–3.62) 1.78 (0.91–3.50)
20–25 (Ref) 1.00 1.00 1.00 1.00
25–30 0.81 (0.60–1.09) 0.77 (0.57–1.04) 0.75 (0.55–1.02) 0.77 (0.56–1.05)
> 30 0.82 (0.60–1.13) 0.73 (0.52–1.02) 0.73 (0.52–1.03) 0.76 (0.54–1.08)
Vintage (years)
< 1 (Ref) 1.00 1.00 1.00
1–4 0.45 (0.31–0.65)**** 0.46 (0.31–0.67)**** 0.48 0.33–0.71)***
> 4 0.36 (0.24–0.52)**** 0.39 (0.26–0.57)**** 0.40 (0.26–0.60)****
Comorbid conditions
Atherosclerotic heart disease (yes vs no) 1.13 (0.81–1.56) 1.11 (0.80–1.55) 1.09 (0.78–1.52)
Diabetes (yes vs no) 1.40 (1.06–1.86)* 1.50 (1.02–2.23)* 1.38 (0.93–2.06)
Hypertension (yes vs no) 0.78 (0.60–1.01) 0.85 (0.65–1.11) 0.86 (0.65–1.13)
Primary cause of kidney disease
Glomerulonephritis (Referent group) 1.00 1.00
Cystic kidney disease 0.37 (0.21–0.67)*** 0.38 (0.21–0.68)**
Diabetes 0.84 (0.50–1.41) 0.85 (0.50–1.43)
Hypertension 0.77 (0.46–1.30) 0.83 (0.49–1.41)
Other cause 1.05 (0.65–1.70) 1.03 (0.63–1.69)
Other urologic 1.15 (0.71–1.85) 1.13 (0.70–1.85)
Unknown/missing 1.29 (0.89–1.87) 1.30 (0.89–1.90)
Laboratory values
Albumin (per 5 g/L) 0.73 (0.59–0.90)**
Pre-dialysis Creatinine (per 50 μmol/L) 0.99 (0.96–1.03)
Model performance
C-Statistic 0.59 0.64 0.67 0.68 0.69
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dependence on CVC by a majority of HD patients.
There is good evidence to suggest that better pre-dialysis
care, more effective organisation of care by multidiscip-
linary teams, and incentivisation schemes lead to greater
creation of AVF over CVCs [22–25]. The fistula first ini-
tiative in the US is an excellent example where national
policy underpinned by a strong regulatory framework
has led a significant increase in AVF use and overall re-
duction in CVC [26–28]. In Ireland, McCann and col-
leagues reported a CVC prevalence of 52% in 2011 from
results of a national survey of vascular access [20]. A dir-
ect comparison with our results 5 years later, highlight
similar prevalence, suggesting that little has changed.
Internationally, CVC use varies significantly among
countries. Among centres participating in the Inter-
national Dialysis Outcomes and Practice Patterns Study
(IDOPPS) between August 2010 and August 2013, CVC
prevalence ranged from 6% in Japan, up to 45% in
Canada. In Europe, Germany had the lowest CVC preva-
lence (15%), while the highest prevalence was noted in
Belgium (38%) [9]. Our prevalence estimate of 54% in
Ireland is one of the highest in Europe, and suggests that
further attention be given to identifying risk factors and
to establishing a framework for corrective action.
The current study draws further attention to centre-
to-centre variation in the clinical practice of vascular
access provision. It is widely acknowledged that some of
this variation in prevalence may be attributed to vari-
ation in the “case-mix” of patients with sicker multi-
morbid patients more likely to receive a CVC than an
AVF. Several patient-related characteristics, including
advanced age, female sex, low serum albumin and
comorbid diseases such as diabetes, are associated with
high CVC use [14–16, 29]. Indeed, our multivariable
Table 3 Unadjusted and multivariable adjusted Odd Ratios and 95% confidence intervals for Central Venous Catheter use (vs Fistula)
(Continued)
Variable Model 1 Model 2 Model 3 Model 4 Model 5
P value of Centre variable 0.0002 0.0002 0.0001 0.0003 0.0001
ANOVA p value for model with and
without Centre variable
– 0.0001 < 0.0001 < 0.0001 < 0.0001
Model 1: dialysis centre only
Model 2: dialysis centre, demographic and lifestyle characteristics (age, sex, and body mass index)
Model 3: dialysis centre, demographic and lifestyle characteristics, dialysis vintage, and comorbid conditions
Model 4: dialysis centre, demographic and lifestyle characteristics (age group, sex, and body mass index), dialysis vintage, and comorbid conditions, and primary
cause of kidney disease
Model 5: dialysis centre, demographic and lifestyle characteristics (age group, sex, and body mass index), dialysis vintage, and comorbid conditions, and primary
cause of kidney disease, and laboratory indicators (serum albumin, and creatinine measured pre-dialysis)
Asterisks denote significant p values: * < 0.05, ** < 0.01, *** < 0.001, **** < 0.0001
Fig. 2 Odd ratios and 95% confidence intervals for dialysis by central venous catheters (versus arteriovenous fistulas) among centres in the Irish health
system. Multivariable model adjusted for demographic factors: sex (female versus male), age group (< 65 (Ref), 65–74 and > 75 years); lifestyle factors:
body mass index group (< 20, 20–25 (Ref), 25–30 and > 30 kg/m2); vintage (< 1 (Ref), 1–4 and > 4 years); comorbid conditions (yes versus no for each):
atherosclerotic heart disease, diabetes, hypertension; primary cause of kidney disease: glomerulonephritis (Ref), cystic kidney disease, diabetes,
hypertension, other cause, other urologic, unknown/missing; and laboratory values: albumin (per 5 g/L) and pre-dialysis creatinine (per 50 μmol/L) .
* denotes statistically significant results
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models, confirmed the relationship of many of these
factors with CVC use. We considered that differences in
the distribution of these patient-level characteristics
across clinical sites might explain some of the observed
variation. However, quite surprisingly, adjusting for these
factors in multivariable models did not attenuate the
effect of dialysis centre on CVC use. The persistence
of variation across clinical sites would suggest that
factors other than comorbidity burden operate to in-
fluence the placement of permanent vascular access.
The structure, organisation, and delivery of HD vas-
cular access care is a complex process and requires
multidisciplinary team engagement with defined care
pathways and embedded quality assurance. The survey
by McCann et al. identified a number of deficits in
the health system including lack of availability of
elective surgical beds and operating room slots, insuf-
ficient vascular access coordinators and access proto-
cols which are likely to impact the timely and
effective creation of AVFs [20]. Physician perspectives,
as well as availability and experience of a vascular
surgeon may also play a role. Internationally, geo-
graphical variability and local facility factors have
been recognized as contributing factors [14–16].
Our study had some limitations that deserve mention.
Unmeasured and residual confounding are inherent
shortcomings given the retrospective nature of the study
and may have contributed to our findings. We acknow-
ledge that other explanatory factors known to affect
fistula placement and maturation such as vessel size
were not available in the dataset, and thus not accounted
for. We also submit that while the cross-sectional nature
of the study allowed us to determine prevalence, it limits
the evaluation of the temporal sequence of events and
thus we cannot determine cause-effect relationships.
These shortcomings were however counterbalanced by
several strengths. First, our study was national in scope
and thus generalizable to all HD patients within the Irish
health system. Second, the KDCPMS is now the primary
clinical data system for recording patient care across all
dialysis centres in Ireland. Consequently, it allowed us to
capture data on key patient-related variables including
demographic characteristics, measures of comorbidity,
dialysis vintage and principal vascular access in a stan-
dardised fashion. Our primary exposure variable, vascu-
lar access type, was determined in real-time from
dialysis treatments which ensured precision. Our ob-
served rates for primary causes of kidney disease and
prevalence of reported comorbid conditions in our
cohort were similar to those reported in other European
countries [30, 31]. Finally, in sensitivity analysis where
we included patients with complete data on all variables,
the findings were materially unchanged (see results in
Additional file 2).
Conclusions
CVCs are the predominant type of vascular access for
Irish patients undergoing chronic HD. These high rates
of CVC use have not changed over the past 5 years. Sub-
stantial variation in CVC use exists across dialysis cen-
tres, which is not explained by measurable patient-
related factors. Findings from this study would suggest
that additional factors, such as patient preference,
limited availability of multidisciplinary vascular access
teams, and lack of timely access to vascular surgical ser-
vices contribute to the high rates of CVC use. Concerted
efforts at a local and national level, informed by national
policy, and international best practice are required to
optimize fistula creation in appropriate patients. We
hope that the findings from this national study will serve
as a catalyst to engage all stakeholders and drive quality
improvement in vascular access.
Additional files
Additional file 1: Table S1. Patient Characteristics Across Dialysis
Centres within the Irish Health System. (DOC 116 kb)
Additional file 2: Sensitivity analyses. (DOC 205 kb)
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